Balaxi Pharmaceuticals Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹106 Cr
- P/E
- 43.51
- ROE
- 0.59%
- PEG
- -0.64
- Price to sales
- 0.39
- Debt to equity
- 0.23
- 52W high / low
- ₹43.1 / ₹15.7
- Sales growth (5Y)
- 3.15%
- EBITDA margin
- 3.22%
- Net profit margin
- 0.53%
- Promoter holding
- 65.99%
- Sales (last year)
- ₹280 Cr
Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines. [1]
Guidance scorecard · Q1 FY27 call
What Balaxi Pharmaceuticals Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
RevenueQ2 FY23 call
20–40%- Revenues for Q2 stood at INR 86.40 crore, with 23% quarter-on-quarter growth, driven by strong volume growth in Latin America.
- Strong expansion expected in established markets like the Dominican Republic and Guatemala.
- Nascent markets such as Honduras and El Salvador are anticipated to scale up revenues in coming quarters.
- Over 745 product registrations currently active in six countries; 646 new registrations submitted or in pipeline.
- Launch of new products planned leading to further improvements in all covered countries.
- EU-GMP compliant manufacturing unit commissioning targeted for March 2024 will boost backward integration and open new markets in Southeast Asia, Central Africa, and Latin America.
2 more points from Balaxi Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ2 FY23 call
FlatSee what Balaxi Pharmaceuticals Ltd said on margins — free account, 30 seconds.
CapexQ2 FY23 call
Planned- Balaxi Pharmaceuticals is setting up an EU-GMP compliant pharmaceutical manufacturing unit near Hyderabad.
- Groundbreaking for the plant is scheduled for December 12, 2022.
- The commissioning of the unit is targeted for March 2024.
- This plant is a backward integration project aimed at reducing product costs.
- Post commissioning, the plant is expected to gain EU-GMP approval within about six months, enabling entry into new markets in Southeast Asia, Central Africa, and Latin America.
- The new facility will support manufacturing of Oral Solid Dosages and Liquid Injectables.
- Capital raised includes INR 49.61 crore through equity and warrants on a preferential basis to partly finance the EU-GMP compliant facility.
2 more points from Balaxi Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ2 FY23 call
PlannedSee what Balaxi Pharmaceuticals Ltd said on fundraising — free account, 30 seconds.
Order bookQ2 FY23 call
Rising- Balaxi Pharmaceuticals currently has 745 product registrations in six countries.
- There are 646 new registrations submitted or in the pipeline to be submitted to various health departments in different countries.
- The company is expecting significant scale-up in revenues from nascent markets like Honduras and El Salvador in coming quarters.
- The new EU-GMP compliant manufacturing plant will enable expansion into new markets (Southeast Asia, Central Africa, Latin America) after approval, potentially increasing order flow and revenues from FY24-25 onwards.
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Balaxi Pharmaceuticals Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Balaxi Pharmaceuticals Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Balaxi Pharmaceuticals Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 86.58 | 80.68 | 65.96 | 54.72 | 60.79 | 59.83 | 65.62 | 77.38 | 73.29 | 76.27 | 70.74 | 56.18 | 72.54 |
| Expenses + | 71.29 | 67.93 | 57.12 | 43.96 | 47.14 | 46.36 | 55.53 | 66.79 | 69.30 | 63.72 | 66.58 | 55.02 | 69.45 |
| Operating Profit | 15.29 | 12.75 | 8.84 | 10.76 | 13.65 | 13.47 | 10.09 | 10.59 | 3.99 | 12.55 | 4.16 | 1.16 | 3.09 |
| OPM % | 17.66% | 15.80% | 13.40% | 19.66% | 22.45% | 22.51% | 15.38% | 13.69% | 5.44% | 16.45% | 5.88% | 2.06% | 4.26% |
| Other Income + | -4.57 | -0.22 | -47.68 | 5.93 | 1.51 | -0.70 | -1.85 | -4.11 | 3.94 | -1.69 | -1.78 | 1.59 | 0.10 |
| Interest | 0.01 | 0.27 | 0.29 | 0.37 | 0.41 | 0.61 | 0.37 | 0.45 | 1.38 | 0.74 | 1.01 | 0.89 | 1.02 |
| Depreciation | 0.19 | 1.19 | 0.29 | 0.66 | 0.48 | 0.67 | 0.49 | 0.46 | 0.48 | 0.46 | 0.46 | 0.48 | 0.56 |
| Profit before tax | 10.52 | 11.07 | -39.42 | 15.66 | 14.27 | 11.49 | 7.38 | 5.57 | 6.07 | 9.66 | 0.91 | 1.38 | 1.61 |
| Tax % | 21.86% | 26.83% | 4.90% | 7.92% | 4.77% | 4.87% | 12.06% | 17.41% | 11.70% | 10.56% | 67.03% | 84.06% | 80.75% |
| Net Profit + | 8.23 | 8.10 | -41.34 | 14.43 | 13.59 | 10.93 | 6.48 | 4.59 | 5.36 | 8.64 | 0.29 | 0.21 | 0.31 |
| EPS in Rs | 1.64 | 1.59 | -8.07 | 2.82 | 2.65 | 2.01 | 1.17 | 0.83 | 0.97 | 1.57 | 0.05 | 0.04 | 0.06 |
Financials of Balaxi Pharmaceuticals Ltd
Profit & Loss
Annual income statement trend
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 14 | 46 | 231 | 279 | 336 | 241 | 293 | 276 |
| Expenses + | 12 | 37 | 189 | 229 | 279 | 197 | 260 | 255 |
| Operating Profit | 2 | 8 | 43 | 51 | 57 | 45 | 32 | 21 |
| OPM % | 11% | 18% | 18% | 18% | 17% | 18% | 11% | 8% |
| Other Income + | 1 | 1 | 2 | 5 | 3 | -38 | 2 | -2 |
| Interest | 0 | 0 | 0 | 1 | 1 | 3 | 4 | 4 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | 2 | 9 | 44 | 55 | 57 | 2 | 29 | 14 |
| Tax % | 19% | 31% | 14% | 13% | 19% | 219% | 13% | |
| Net Profit + | 2 | 6 | 38 | 48 | 46 | -2 | 25 | 9 |
| EPS in Rs | 1.30 | 1.22 | 7.63 | 9.53 | 9.03 | -0.44 | 4.54 | 1.72 |
| Dividend Payout % | 0% | 0% | 0% | 1% | 0% | 0% | 0% |
Financials of Balaxi Pharmaceuticals Ltd
Balance Sheet
Capital structure and asset base
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 10 | 10 | 10 | 10 | 11 | 11 | 11 |
| Reserves | 0 | 18 | 55 | 103 | 173 | 190 | 221 | 227 |
| Borrowings + | 0 | 0 | 4 | 4 | 13 | 19 | 53 | 57 |
| Other Liabilities + | 3 | 8 | 31 | 60 | 43 | 38 | 25 | 28 |
| Total Liabilities | 6 | 36 | 100 | 176 | 240 | 258 | 310 | 322 |
| Fixed Assets + | 0 | 0 | 2 | 29 | 41 | 41 | 41 | 45 |
| CWIP | 0 | 0 | 0 | 1 | 3 | 2 | 22 | 34 |
| Investments | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 6 | 36 | 94 | 147 | 195 | 215 | 247 | 244 |
| Total Assets | 6 | 36 | 100 | 176 | 240 | 258 | 310 | 322 |
Financials of Balaxi Pharmaceuticals Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -2 | -14 | 0 | 34 | 6 | 5 | -35 |
| Cash from Investing Activity + | -0 | -0 | -6 | -28 | -11 | -1 | -22 |
| Cash from Financing Activity + | 0 | 18 | 4 | -0 | 26 | 30 | 34 |
| Net Cash Flow | -2 | 4 | -2 | 6 | 21 | 34 | -23 |
| Free Cash Flow | -2 | -14 | -3 | 7 | -9 | 4 | -57 |
| CFO/OP | -97% | -161% | 6% | 78% | 32% | 26% | -98% |
Financials of Balaxi Pharmaceuticals Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 147 | 238 | 121 | 36 | 57 | 84 | 138 |
| Inventory Days | 9 | 29 | 184 | 189 | 233 | 173 | |
| Days Payable | 64 | 53 | 92 | 62 | 82 | 36 | |
| Cash Conversion Cycle | 147 | 183 | 97 | 129 | 184 | 235 | 275 |
| Working Capital Days | 82 | 181 | 91 | 92 | 122 | 142 | 186 |
| ROCE % | 57% | 93% | 60% | 37% | 21% | 13% |
Guidance history
How Balaxi Pharmaceuticals Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q2 FY23 call → | 20–40% | Flat | Planned | Planned | Rising |
| Q1 FY23 call → | 40%+ | Flat | Planned | Planned | Rising |
| Q3 FY21 call → | 20–40% | Flat | None planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Continue your research
What Balaxi Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
- Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
- IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL